AZD7507

Research use only, not for human use.

AZD7507 (AZD-7507) is a potent, selective, orally available CSF-1R (c-FMS) with IC50 of 32 nM.

AZD7507 (AZD-7507) is a potent, selective, orally available CSF-1R (c-FMS) with IC50 of 32 nM; demonstrates cleaner secondary pharmacology profiles, demonstrates good rat oral PK, with in vivo clearance of 7 ml/min/kg and 42% bioavailability; has an IC50 >20 uM in the canine L-type Ca channel assays; causes shrinkage of established tumors and increases mouse survival in genetic PDAC model.

AZD7507 (Compound 31) inhibits the proliferation of 3T3 cells engineered to express CSF-1R and stimulated with CSF-1 (IC50, 32 nM), shows inhibitory activity against hERG and NaV1.5, with IC50s of >30 and 26 μM.

AZD7507 has good rat oral PK, with in vivo clearance of 7 mL/min/kg and 42% bioavailability. In the canine L-type Ca channel assay, the IC50 is >20 μM. AZD7507 significantly decreases the number of CD68+ macrophages in mice, and also reduces the volume and mass in mice bearing CC-LP-1 and SNU-1079 cells, but not WITT-1 cells.

AZD-7507 | AZD 7507

Tyrosine Kinase

CSF1R

CSF1R

——

——

1041852-85-0

454.506

C23H27FN6O3

>98% (HPLC)

DMSO : 130 mg/mL 286.03 mM;

O=C(C1=NN=C2C=C(OC)C(N3CCN(CCO)CC3)=CC2=C1NC4=CC=C(C)C=C4F)N

4-(2-fluoro-4-methylanilino)-6-[4-(2-hydroxyethyl)piperazin-1-yl]-7-methoxycinnoline-3-carboxamide

(-20℃)

With Ice Pack

≥ 2 years